{"id":6986,"date":"1970-01-01T00:00:00","date_gmt":"1970-01-01T00:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-resultats-financiers-du-premier-semestre-2014\/"},"modified":"1970-01-01T00:00:00","modified_gmt":"1970-01-01T00:00:00","slug":"nicox-resultats-financiers-du-premier-semestre-2014","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/","title":{"rendered":"Nicox : r\u00e9sultats financiers du premier semestre 2014"},"content":{"rendered":"<ul>\n<li>\n  Le chiffre d\u2019affaires du premier semestre s\u2019\u00e9l\u00e8ve \u00e0 \u20ac2,6 millions et refl\u00e8te la premi\u00e8re contribution compl\u00e8te d\u2019Eupharmed et des produits ophtalmiques lanc\u00e9s r\u00e9cemment par Nicox&nbsp;<\/li>\n<li>\n  Lancements nationaux des tests de diagnostic Sj\u00f6\u2122 et RetnaGene\u2122 aux Etats-Unis<\/li>\n<li>\n  D\u00e9marrage des activit\u00e9s europ\u00e9ennes et internationales avec les lancements d\u2019AdenoPlus\u00ae et Xailin\u2122<\/li>\n<li>\n  Premiers r\u00e9sultats de phase 3 du latanoprost\u00e8ne bunod attendus d\u2019ici la fin de l\u2019ann\u00e9e<\/li>\n<li>\n  Projet d\u2019acquisition d\u2019Aciex Therapeutics, Inc, nouvelle \u00e9tape majeure dans la strat\u00e9gie de Nicox visant \u00e0 cr\u00e9er une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, avec des m\u00e9dicaments et des tests de diagnostic&nbsp;<\/li>\n<\/ul>\n<div>\n Sophia Antipolis, France.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Conference t\u00e9l\u00e9phonique du 28 ao\u00fbt 2014<\/strong><\/div>\n<ul>\n<li>\n  <strong><a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/hy2014_ccall_french_final.pdf\">Pr\u00e9sentation<\/a>&nbsp;(PDF)<\/strong><\/li>\n<li>\n  <strong><a href=\"ftp:\/\/8033244:3859523@ftp.eupgi.com\">Enregistrement audio<\/a> (MP3)&nbsp;<\/strong><\/li>\n<\/ul>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Nicox S.A.<\/strong> (NYSE Euronext Paris: COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, publie aujourd\u2019hui ses r\u00e9sultats financiers pour les six premiers mois de l\u2019ann\u00e9e 2014 et pr\u00e9sente une vue d\u2019ensemble de ses activit\u00e9s.<\/div>\n<div>\n &nbsp;<\/div>\n<div>\n <strong>Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox,<\/strong> a d\u00e9clar\u00e9 : \u00ab<em> Au cours du premier semestre, nous avons continu\u00e9 d\u2019appliquer notre strat\u00e9gie de construction d\u2019une nouvelle soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie. Notre chiffre d\u2019affaires commence \u00e0 cro\u00eetre, avec le lancement de nouveaux produits au travers de notre infrasctructure commerciale aux Etats-Unis et en Europe, et nous pensons que la progression des ventes va se poursuivre au cours du second semestre.&nbsp;<\/em><em>Le projet d\u2019acquisition d\u2019Aciex Therapeutics va nettement renforcer nos efforts pour construire un portefeuille solide de produits th\u00e9rapeutiques aux c\u00f4t\u00e9s de nos tests de diagnostic. Cette acquisition apportera un portefeuille de technologies th\u00e9rapeutiques et de m\u00e9dicaments en d\u00e9veloppement dans le domaine de l\u2019ophtalmologie, dont l\u2019AC-170 en phase 3 pour la conjonctivite allergique. De plus, nous attendons avec impatience les premiers r\u00e9sultats d\u2019efficacit\u00e9 de phase 3 pour le latanoprostene bunod de notre partenaire Bausch + Lomb (Valeant) d\u2019ici la fin de l\u2019ann\u00e9e. Il s\u2019agit du compos\u00e9 le plus avanc\u00e9 et le plus prometteur en d\u00e9veloppement pour le traitement potentiel de la PIO \u00e9lev\u00e9e et du glaucome.<\/em> \u00bb<\/div>\n<div>\n &nbsp;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le chiffre d\u2019affaires du premier semestre s\u2019\u00e9l\u00e8ve \u00e0 \u20ac2,6 millions et refl\u00e8te la premi\u00e8re contribution compl\u00e8te d\u2019Eupharmed et des produits ophtalmiques lanc\u00e9s r\u00e9cemment par Nicox&nbsp; Lancements nationaux des tests de diagnostic Sj\u00f6\u2122 et RetnaGene\u2122 aux Etats-Unis D\u00e9marrage des activit\u00e9s europ\u00e9ennes et internationales avec les lancements d\u2019AdenoPlus\u00ae et Xailin\u2122 Premiers r\u00e9sultats de phase 3 du latanoprost\u00e8ne [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6986","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Le chiffre d\u2019affaires du premier semestre s\u2019\u00e9l\u00e8ve \u00e0 \u20ac2,6 millions et refl\u00e8te la premi\u00e8re contribution compl\u00e8te d\u2019Eupharmed et des produits ophtalmiques lanc\u00e9s r\u00e9cemment par Nicox&nbsp; Lancements nationaux des tests de diagnostic Sj\u00f6\u2122 et RetnaGene\u2122 aux Etats-Unis D\u00e9marrage des activit\u00e9s europ\u00e9ennes et internationales avec les lancements d\u2019AdenoPlus\u00ae et Xailin\u2122 Premiers r\u00e9sultats de phase 3 du latanoprost\u00e8ne [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"1970-01-01T00:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : r\u00e9sultats financiers du premier semestre 2014\",\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/\",\"name\":\"Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2014\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox","og_description":"Le chiffre d\u2019affaires du premier semestre s\u2019\u00e9l\u00e8ve \u00e0 \u20ac2,6 millions et refl\u00e8te la premi\u00e8re contribution compl\u00e8te d\u2019Eupharmed et des produits ophtalmiques lanc\u00e9s r\u00e9cemment par Nicox&nbsp; Lancements nationaux des tests de diagnostic Sj\u00f6\u2122 et RetnaGene\u2122 aux Etats-Unis D\u00e9marrage des activit\u00e9s europ\u00e9ennes et internationales avec les lancements d\u2019AdenoPlus\u00ae et Xailin\u2122 Premiers r\u00e9sultats de phase 3 du latanoprost\u00e8ne [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/","og_site_name":"Nicox","article_published_time":"1970-01-01T00:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/"},"author":{"name":"","@id":""},"headline":"Nicox : r\u00e9sultats financiers du premier semestre 2014","datePublished":"1970-01-01T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/"},"wordCount":387,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/","url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/","name":"Nicox : r\u00e9sultats financiers du premier semestre 2014 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"1970-01-01T00:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2014\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6986"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}